Pacific Biosciences
PACB
Market cap $468M

1.56 USD

+0.02

1.30%

Updated Jul 30, 1:01 PM EDT

1 day

1.30%

5 days

-6.59%

1 month

25.81%

3 months

40.54%

6 months

-2.50%

Year to date

-13.33%

1 year

-23.90%

5 years

-58.62%

10 years

-71.84%

About: Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Employees: 575

Healthcare Medical Devices

0

Funds holding %

of 7,323 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

148% more call options, than puts

Call options by funds: $4.29M | Put options by funds: $1.73M

3% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 35

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]

1% less funds holding

Funds holding: 225 [Q4 2024] → 222 (-3) [Q1 2025]

19.2% less ownership

Funds ownership: 94.77% [Q4 2024] → 75.57% (-19.2%) [Q1 2025]

22% less repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 73

44% less capital invested

Capital invested by funds: $475M [Q4 2024] → $265M (-$210M) [Q1 2025]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$1.25

20%

downside

Avg. target

$1.52

3%

downside

High target

$1.80

15%

upside

3 analyst ratings

1 positive

33%

2 neutral

67%

0 negative

0%

Barclays Luke Sergott	4%downside $1.50	Equal-Weight Maintained	25 Jun 2025
Piper Sandler David Westenberg	20%downside $1.25	Neutral Maintained	15 May 2025
Stephens & Co. Mason Carrico	15%upside $1.80	Overweight Reiterated	15 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about PACB published over the past 30 days

Zacks Investment Research

Pacific Biosciences of California (PACB) Suffers a Larger Drop Than the General Market: Key Insights

Pacific Biosciences of California (PACB) reached $1.54 at the closing of the latest trading day, reflecting a -6.1% change compared to its last close.

Pacific Biosciences of California (PACB) Suffers a Larger Drop Than the General Market: Key Insights

Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing

New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease BOSTON , July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology business of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a new laboratory test service intended to provide insights into genetic causes of ataxia, a group of progressive, degenerative neurological disorders that affect movement or coordination. The new service is a laboratory developed test that identifies sequences of DNA that repeat many times across a long stretch of the genome.

Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing

PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications

Study reveals millions of previously unknown variants and genomic sequences from underrepresented populations Study reveals millions of previously unknown variants and genomic sequences from underrepresented populations

PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications

PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequencing with Kinnex and Revio

New Iso-Seq data from ~1,000 samples to expand transcriptomic insights using highly accurate HiFi sequencing New Iso-Seq data from ~1,000 samples to expand transcriptomic insights using highly accurate HiFi sequencing

PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequencing with Kinnex and Revio

PacBio to Report Second Quarter 2025 Financial Results on August 7, 2025

MENLO PARK, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2025 financial results on Thursday, August 7, 2025, at 5:00 pm Eastern Time.

PacBio to Report Second Quarter 2025 Financial Results on August 7, 2025

Zacks Investment Research

Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know

The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.5, representing a +1.35% change from its previous close.

Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know

Zacks Investment Research

Here's Why You Should Add PacBio Stock to Your Portfolio Now

PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset macroeconomic concerns and drive 2025 growth.

Here's Why You Should Add PacBio Stock to Your Portfolio Now

Zacks Investment Research

Pacific Biosciences (PACB) Upgraded to Strong Buy: Here's What You Should Know

Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Pacific Biosciences (PACB) Upgraded to Strong Buy: Here's What You Should Know

Zacks Investment Research

Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know

Pacific Biosciences of California (PACB) closed at $1.18 in the latest trading session, marking a +1.72% move from the prior day.

Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know

Zacks Investment Research

Here's Why You Should Add PacBio Stock to Your Portfolio Now

PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.

Here's Why You Should Add PacBio Stock to Your Portfolio Now

See News Rankings

Charts implemented using Lightweight Charts™